Jpmorgan Chase & CO Aerovate Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 67,165 shares of AVTE stock, worth $164,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,165

Previous 5,991 1021.1%

Holding current value

$164,554

Previous $12,000 1375.0%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$1.99 - $2.79 $121,736 - $170,675	61,174 Added 1021.1%	67,165 $177,000
Q3 2024 Dec 26, 2024	BUY	$1.61 - $2.09 $264 - $342	164 Added 2.81%	5,991 $12,000
Q3 2024 Nov 08, 2024	BUY	$1.61 - $2.09 $264 - $342	164 Added 2.81%	5,991 $12,000
Q2 2024 Dec 26, 2024	SELL	$1.41 - $30.75 $231 - $5,043	-164 Reduced 2.74%	5,827 $9,000
Q2 2024 Aug 12, 2024	BUY	$1.41 - $30.75 $1,742 - $38,007	1,236 Added 26.92%	5,827 $9,000
Q1 2024 Dec 26, 2024	SELL	$17.68 - $29.57 $24,752 - $41,398	-1,400 Reduced 23.37%	4,591 $135,000
Q1 2024 May 10, 2024	SELL	$17.68 - $29.57 $51,006 - $85,309	-2,885 Reduced 38.59%	4,591 $135,000
Q4 2023 Dec 26, 2024	BUY	$9.58 - $24.25 $14,226 - $36,011	1,485 Added 24.79%	7,476 $169,000
Q4 2023 Feb 12, 2024	BUY	$9.58 - $24.25 $546 - $1,382	57 Added 0.77%	7,476 $169,000
Q3 2023 Nov 14, 2023	SELL	$12.9 - $18.88 $8,397 - $12,290	-651 Reduced 8.07%	7,419 $100,000
Q2 2023 Aug 11, 2023	BUY	$15.63 - $22.01 $15,411 - $21,701	986 Added 13.92%	8,070 $138,000
Q1 2023 May 18, 2023	BUY	$19.17 - $27.7 $134,841 - $194,841	7,034 Added 14068.0%	7,084 $142,000
Q1 2023 May 11, 2023	SELL	$19.17 - $27.7 $100,009 - $144,510	-5,217 Reduced 99.05%	50 $1,000
Q4 2022 Feb 13, 2023	SELL	$15.92 - $30.52 $24,787 - $47,519	-1,557 Reduced 22.82%	5,267 $154,000
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $14,001 - $24,448	948 Added 16.13%	6,824 $113,000
Q2 2022 Aug 11, 2022	SELL	$10.8 - $16.91 $33,814 - $52,945	-3,131 Reduced 34.76%	5,876 $92,000
Q1 2022 May 11, 2022	BUY	$8.25 - $18.33 $24,708 - $54,898	2,995 Added 49.82%	9,007 $165,000
Q4 2021 Feb 10, 2022	BUY	$9.14 - $21.54 $7,037 - $16,585	770 Added 14.69%	6,012 $71,000
Q3 2021 Nov 12, 2021	BUY	$11.76 - $22.49 $61,645 - $117,892	5,242 New	5,242 $110,000

Others Institutions Holding AVTE

# of Institutions

Shares Held

31.3M

Call Options Held

117K

Put Options Held

245K

View Full List

About Aerovate Therapeutics, Inc.

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $59.9M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

More about AVTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Aerovate Therapeutics, Inc. Transaction History